245 related articles for article (PubMed ID: 15676299)
1. High-throughput target discovery using cell-based genetics.
Jackson PD; Harrington JJ
Drug Discov Today; 2005 Jan; 10(1):53-60. PubMed ID: 15676299
[TBL] [Abstract][Full Text] [Related]
2. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
3. Yeast genomics and proteomics in drug discovery and target validation.
Parsons AB; Geyer R; Hughes TR; Boone C
Prog Cell Cycle Res; 2003; 5():159-66. PubMed ID: 14593709
[TBL] [Abstract][Full Text] [Related]
4. Integrated approaches to therapeutic target gene discovery.
DeFife KM; Wong-Staal F
Curr Opin Drug Discov Devel; 2002 Sep; 5(5):683-9. PubMed ID: 12630288
[TBL] [Abstract][Full Text] [Related]
5. High-throughput virtual screening for drug discovery in parallel.
Toledo-Sherman LM; Chen D
Curr Opin Drug Discov Devel; 2002 May; 5(3):414-21. PubMed ID: 12058617
[TBL] [Abstract][Full Text] [Related]
6. The ATCG of drug discovery.
Fernandes PB
Curr Opin Mol Ther; 2000 Dec; 2(6):624-32. PubMed ID: 11249739
[TBL] [Abstract][Full Text] [Related]
7. Towards quantitative biology: integration of biological information to elucidate disease pathways and to guide drug discovery.
Fischer HP
Biotechnol Annu Rev; 2005; 11():1-68. PubMed ID: 16216773
[TBL] [Abstract][Full Text] [Related]
8. Tools for target identification and validation.
Wang S; Sim TB; Kim YS; Chang YT
Curr Opin Chem Biol; 2004 Aug; 8(4):371-7. PubMed ID: 15288246
[TBL] [Abstract][Full Text] [Related]
9. Towards high-throughput characterization of small molecule mechanisms of action.
Luesch H
Mol Biosyst; 2006 Dec; 2(12):609-20. PubMed ID: 17216042
[TBL] [Abstract][Full Text] [Related]
10. Where are we in genomics?
Hocquette JF
J Physiol Pharmacol; 2005 Jun; 56 Suppl 3():37-70. PubMed ID: 16077195
[TBL] [Abstract][Full Text] [Related]
11. Druggable targets and targeted drugs: enhancing the development of new therapeutics.
Billingsley ML
Pharmacology; 2008; 82(4):239-44. PubMed ID: 18802381
[TBL] [Abstract][Full Text] [Related]
12. Genomics and proteomics tools for compound mode-of-action studies in drug discovery.
Kley N; Ivanov I; Meier-Ewert S
Pharmacogenomics; 2004 Jun; 5(4):395-404. PubMed ID: 15165175
[TBL] [Abstract][Full Text] [Related]
13. Structure and organization of drug-target networks: insights from genomic approaches for drug discovery.
Janga SC; Tzakos A
Mol Biosyst; 2009 Dec; 5(12):1536-48. PubMed ID: 19763339
[TBL] [Abstract][Full Text] [Related]
14. Cancer cell-based genomic and small molecule screens.
Caldwell JS
Adv Cancer Res; 2007; 96():145-73. PubMed ID: 17161679
[TBL] [Abstract][Full Text] [Related]
15. Large-scale integrated databases supporting drug discovery.
Roter AH
Curr Opin Drug Discov Devel; 2005 May; 8(3):309-15. PubMed ID: 15892245
[TBL] [Abstract][Full Text] [Related]
16. siRNAs in drug discovery: target validation and beyond.
Natt F
Curr Opin Mol Ther; 2007 Jun; 9(3):242-7. PubMed ID: 17608022
[TBL] [Abstract][Full Text] [Related]
17. Genomics and proteomics in process development: opportunities and challenges.
Gupta P; Lee KH
Trends Biotechnol; 2007 Jul; 25(7):324-30. PubMed ID: 17475353
[TBL] [Abstract][Full Text] [Related]
18. Genomics in drug discovery: the best things come to those who wait.
Bansal AT; Barnes MR
Curr Opin Drug Discov Devel; 2008 May; 11(3):303-11. PubMed ID: 18428083
[TBL] [Abstract][Full Text] [Related]
19. The multiple orthogonal tools approach to define molecular causation in the validation of druggable targets.
Hardy LW; Peet NP
Drug Discov Today; 2004 Feb; 9(3):117-26. PubMed ID: 14960389
[TBL] [Abstract][Full Text] [Related]
20. Array-based proteomics: high-throughput expression and purification of IMAGE consortium cDNA clones.
Albala JS; Humphery-Smith I
Curr Opin Mol Ther; 1999 Dec; 1(6):680-4. PubMed ID: 19629864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
